The novel transcriptional target of TEAD4, RBM8A, also interacts with EIF4A3 to increase the expression of IGF1R and IRS-2 and activate the PI3K/AKT signaling pathway, which further promotes the malignant phenotype of BC cells (33). Here, EIF4A3 is linked to breast cancer.